A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

标题

A phase 3, multicenter, randomized, double-blind, placebo-controlled study of rilotumumab in combination with cisplatin and capecitabine (CX) as first-line therapy for Asian patients (pts) with advanced MET-positive gastric or gastroesophageal junction (G/GEJ) adenocarcinoma: The RILOMET-2 trial.

作者

关键词

-

出版物

JOURNAL OF CLINICAL ONCOLOGY

Volume 33, Issue 3_suppl, Pages TPS226-TPS226

出版商

American Society of Clinical Oncology (ASCO)

发表日期

2017-02-24

DOI

10.1200/jco.2015.33.3_suppl.tps226